Intravacc Signs Exclusive License Agreement with Zhifei Lvzhu Biopharmaceutical to Commercialize Avacc 3

0
  • Avac 3 has significant advantages over existing pertussis vaccines
  • Second major licensing agreement of the OMV platform with a pharmaceutical company
  • Over 24 million pertussis cases per year worldwide

BILTHOVEN, Netherlands, May 2, 2022 /PRNewswire/ — Intravac BV, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the signing of an exclusive licensing agreement with Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (“Zhifei Lvzhu”) in China for Avac 3, an OMV-based pertussis vaccine.

Under this agreement, Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and some Asian countries. Under the agreement, Intravacc will receive milestone and upfront payments and net sales royalties. The two parties will continue to collaborate to adapt the Avac 3 concept vaccine to the respective territories, including scale-up, toxicology and clinical trials.

Current pertussis vaccines have drawbacks. Whole-cell inactivated vaccines are relatively reactogenic, which limits their use in immunization programs. Subunit vaccines, on the other hand, have limited efficacy. This results in outbreaks of whooping cough, even in vaccinated populations. Asymptomatic carriage facilitates the spread of the bacteria and a vaccine that prevents it could help protect the herd. Avacc 3 from Intravacc, a counterpart Whooping cough Bordetella candidate vaccine based on Intravacc’s OMV platform, induces a strong systemic immune response. When administered intranasally, it induces both a strong systemic immune response and a strong mucosal immune response.

dr. John GreenCEO of Intravacc, said:

We are very pleased to partner with Zhifei to help improve whooping cough prevention by China. This is Intravacc’s second OMV-based licensing agreement with a pharmaceutical company, expanding the global reach of our proprietary OMV platform technology.

Whooping cough Bordetella

Pertussis, or whooping cough, is a highly contagious respiratory disease caused by gram-negative bacteria Whooping cough Bordetella and transmitted by Flügges droplets. It is a strictly human pathogen and all age groups can be infected. However, infants are the main risk group. Worldwide, there are an estimated 24 million cases of whooping cough and approximately 160,000 deaths per year. Diagnosis of whooping cough is often difficult in the early stage with only a mild cough, and fever is rare. Later, the severity of the disease increases with pneumonia, vomiting and increased coughing, which in infants can lead to death.

About Intravacc’s OMV Platform Technology

For vaccine development, Intravacc has designed and developed a platform based on Outer Membrane Vesicles (OMVs) – spherical particles with intrinsic adjuvant properties. OMVs can be equipped with immunogenic peptides and/or proteins that stimulate effective adaptive immunity. The OMV transporter has been optimized to induce a more efficient immune response against these newly introduced antigens. Intravacc has also developed genetic tools to increase OMV yield, reduce toxicity and achieve the desired antigenic composition. Intravacc’s OMV platform is fully scalable and enables rapid and efficient modification of antigenic composition, either by genetic modification of the bacterial host or by associating antigens with stored OMVs.

About Intravacc BV

Intravacc, located at Utrecht Science Park Bilthoven at the Netherlands, is one of the world’s leading contract development and manufacturing organizations (CDMOs) of innovative infectious disease vaccines. As an established independent CDMO with over 100 years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology related to poliomyelitis vaccines, measles vaccines, DTP vaccines, Hib vaccines and flu vaccines worldwide. Approximately 40% of childhood disease vaccines are based on Intravacc’s proprietary technology. Intravacc offers a wide range of expertise to develop vaccines from concept to phase I/II clinical studies for partners around the world, including universities, public health organizations (WHO, Bill & Melinda Gates Foundation), corporations biotechnology and pharmaceuticals. For more information, please visit www.intravacc.nl.

About Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd.

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is one of the largest vaccine companies in China which specializes in R&D, manufacturing and marketing of human vaccines targeting meningitis, pneumonia, diphtheria, tetanus and pertussis (DTP) and contained DTP vaccines, diarrhea (Shigellosis), etc. Since 2008, more than 110 million doses of vaccines produced by Zhifei Lvzhu have been donated to needed people around the world.

Zhifei Lvzhu is a wholly owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. (SZSE: 300122, “Zhifei” for short), one of the world’s leading vaccine suppliers and service providers. The company has 6 self-developed vaccines and biologicals currently on the market, including the recombinant COVID-19 (CHO cell) vaccine (Zifivax®), with more than 290 million doses distributed worldwide, making a positive contribution to the global fight against the covid19 pandemic.

For more information, please visit www.zhifeishengwu.com.

Contact information

Intravac
dr. John GreenCEO
Such. : +31 30 7920 454

Mirjam HartmannMedia Relations
Such. : +31 6 115 969 94
E: [email protected]

LifeSpring Life Science Communication, amsterdam
Leon Melens
Such. : +31 6 538 16427
E: [email protected]

Logo – https://mma.prnewswire.com/media/1334670/Intravacc_Logo.jpg

SOURCE Intravac

Share.

Comments are closed.